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Abstract
Estrogen has anti-colorectal cancer effects which are 
thought to be mediated by mismatch repair gene 
(MMR) activity. Estrogen receptor (ER) expression is 
associated with microRNA (miRNA) expression in 
ER-positive tumors. However, studies of direct link 
between estrogen (especially estradiol E2), miRNA 
expression, and MMR in colorectal cancer (CRC) have 
not been done. In this study, we first evaluated the 
effects of estradiol (E2) and its antagonist ICI182,780 on 
the expression of miRNAs (miR-31, miR-155 and 
miR-135b) using COLO205, SW480 and MCF-7 cell 
lines, followed by examining the association of tissue 
miRNA expression and serum E2 levels using samples 
collected from 18 colorectal cancer patients. E2 
inhibited the expressions of miRNAs in COLO205 cells, 
which could be reversed by E2 antagonist ICI 182.780. 
The expression of miR-135b was inversely correlated 
with serum E2 level and ER-β mRNA expression in CRC 
patients’ cancer tissues. There were significant 
correlations between serum E2 level and expression of 
ER-β, miR-135b, and MMR in colon cancer tissue. This 
study suggests that the effects of estrogen on MMR 
function may be related to regulating miRNA 
expression via ER-β, which may be the basis for the 
anti-cancer effect in colorectal cells. 
Keywords: colon neoplasms; DNA mismatch repair; 
estrogen receptor β; estrogen; microRNAs 
Introduction
Colorectal cancer (CRC) is the fourth most common 
cause of death from cancer, affects around 1.2 million 
people world wide, with about 608,700 fatalities per 
year (Ferlay et al., 2010). Both the prevalence (Ries 
et al., 2000) and the lifetime risk of CRC (Froggatt et 
al., 1999) are significantly lower in females than in 
males. This is particularly true when comparing 
pre-menopausal women to age-matched men. The 
sex-specific difference in CRC incidence has been 
attributed to estrogen (Chlebowski et al., 2004). 
Estrogen exerts its effects mainly through two members 
of the estrogen receptor (ER) superfamily, ER-α and 
ER-β. ER-α expression is low in normal colonic 
mucosa and colon cancer cells, while ER-β is 
predominant in human colonic mucosal cells. ER-β is 
significantly decreased in colonic neoplasms 
compared to normal colonic mucosa. Decreased 
ER-β expression may lead to hyperproliferation, 
decreased differentiation, and decreased apoptosis 
of colonic epithelial cells (Maria and Paola, 2008), 
suggesting that ER-β is likely to be involved in the 
regulation of colonic tumor growth.
    DNA mismatch repair (MMR) system plays an 
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important role in maintaining genomic stability. The 
MMR gene alteration including genetic and sporadic 
mutations, commonly occur in the early stages of 
the neoplastic process. MMR dysfunction can cause 
microsatellite instability (MSI). It has been reported 
that estrogen is associated with MSI (Slattery et al., 
2001). In our previous study, estradiol (E2) has 
shown to up-regulate major MMR gene (hMLH1) 
activity in colonic epithelial cells (Jin et al., 2010). 
These findings suggest that estrogen’s anti-colorectal 
cancer effect may be mediated by MMR function in 
colonic cells. However, the pathway through which 
estrogen regulates MMR function is still not well 
understood.
    MicroRNAs (miRNAs), a series of small noncoding 
RNAs of 19 to 22 nucleotides, are involved in many 
important cellular processes such as development, 
differentiation, proliferation, cell cycle progression, 
apoptosis, inflammation, and stress response (Lee 
and Dutta, 2009; Lu and Liston, 2009; Wang and 
Lee, 2009). Since expression alterations of some 
miRNAs are associated with a series of genetic 
events, their expression patterns may either have 
pro- or anti- cancer effects (He et al., 2005; Johnson 
et al., 2005; O’Donnell et al., 2005). Several 
miRNAs expression alterations have been reported 
in CRC, including miR-135b, miR-96, miR-183, 
miR-133a, miR-133b, miR-21, miR-31, miR-145, 
miR-203, miR-223, miR-155, etc (Bandres et al., 
2006; Cummins et al., 2006; Volinia et al., 2006; 
Lanza et al., 2007; Sarver et al., 2009). However, 
the mechanism for miRNA change in CRC is not 
well understood. Recent studies have indicated that 
estrogens can regulate miRNAs expression in 
human breast cancer cells, endometrial stromal 
cells, and myometrial smooth muscle cells (Pan et 
al., 2007; Wickramasinghe et al., 2009). Therefore, 
we hypothesize that estrogen may have similar 
effects on miRNAs expression in colorectal epithelial 
cells. 
    In this study, we investigated the relationships of 
Estradiol, ER-β, and the expression of MMR genes 
(hMLH1 and hMSH2) and miRNA in cultured 
human colon cancer cells (COLO205 and SW480), 
human breast cancer cells (MCF-7) and patient 
tissue/serum samples. Our findings suggest that 
estrogen, through ER-β, regulates miRNA and 
MMR expression. 
Results
Apoptosis induced by E2 in COLO205 and SW480
After treatment with different concentrations of E2 for 
48 h, the apoptotic cells (Annexin-V+/PI-) were 
significantly increased in COLO205 (high levels of 
ER-β expression, and no ER-α expression cells) 
(Qiu et al., 2002) with a dose-dependent manner 
between 1×10-6 and 1× 10-10 M of E2, and the 
effect was the strongest at 1×10-9 M of E2 (Figure 
1A) (P＜ 0.001). Estrogen receptor antagonist, 
ICI182,780, inhibited E2-induced apoptosis in 
COLO205 cells (Figure 1B). However, the effect of 
E2 on apoptotic induction was not seen in SW480 
which has very low levels of ER-β expression cells 
(Figure 1C) (Hartman et al., 2009). The finding 
shows that estrogen’s apoptosis induction effect 
appears to be specifically in ER-β expression cells. 
Effect of E2 on the expression of miRNAs in vitro 
The expression levels of miR-31, miR-155, miR-135b, 
miR-203 and miR-223 in COLO205 cells were then 
determined before and after the treatment by E2, 
respectively. RT-qPCR results indicated that E2 
decreased the levels of miR-31, miR-155 and 
miR-135b in a time-dependent manner (Figure 2A). 
To determine if the reduction of these miRNAs by E2 
was mediated by estrogen receptor, COLO205 cells 
were pre-incubated with 100 nM estrogen antagonist 
ICI182,780 for 6 h, followed by E2 incubation. Our 
results indicated that ICI182,780 reversed E2-induced 
repression of miR-31, miR-155 and miR-135b 
(Figure 2B). E2 did not however affect miRNA 
expression in either SW480 cells, which is known to 
have very low levels of ER-β, or MCF-7 cells, in 
which ER-α represents the largely predominant 
form, while ER-β is only barely detectable (Figures 
2C and 2D) (Perillo et al., 2000; Hartman et al., 
2009; Wilkins et al., 2010). The findings suggest that 
the differential effect of E2 on miRNA expression in 
different cell lines relates to the ER-β, or the ratio of 
ER-β to ER-α. 
Effect of E2 on the expression of ER-β, hMLH1 and 
hMSH2 in vitro 
RT-qPCR and Western blotting showed that E2 
increased the expression of ER-β and hMLH1, but at 
less degree of hMSH2, at both mRNA and protein 
levels in COLO205 cells, in a time and 
dose-dependent manners (Figures 3A and 3D). 
These effects were again inhibited by ICI182,780 
(Figure 3B). No changes in the expression of 
hMLH1, hMSH2 and ER-β mRNA were seen in 
MCF-7 and SW480 cells (Figures 3C and 3D). The 
results suggest that E2, via ER-β, inhibits miRNA 
and increases hMLH1 expression in COLO205 cells.
 Estrogen regulates microRNA and DNA repair    725
Figure 1. Effect of Estrogen (E2) on apoptosis induction in COLO205 and SW480 cells. Apoptosis was determined by FITC-conjugated Annexin-V/PI as-
say kit (Abcam) and flow cytometry. COLO205 cells treated with 10-6-10-10 M of E2 (A) and estrogen antagonist, ICI182,780, prior to incubation with E2 (B) . 
SW480 cells treated with E2 (C). The cells sorted at the Annexin-V+/PI- fraction (bottom right quadrant) were early apoptotic cells. Mean± SD from 3 in-
dependent experiments.
Effect of E2 on MMR and several miRs in ER-β 
over-expression cells
To confirm the regulation effects of E2 on MMR and 
several miRs were mediated through ERbeta, we 
transfected ER-β plasma to up-regulate ER-β 
expression in SW480 cells. ERbeta protein expression 
was not up-regulated in vector transfected SW480 
cells, whereas it was up-regulated in pRST7-ER-β 
transfected SW480 cells after 24 and 48 h of 
transfection by immunoblot (Figure 4A). RT-qPCR 
results indicated that E2 decreased the levels of 
miR-31, miR-155 and miR-135b in pRST7-ER-β 
transfected SW480 cells, but not in vector cells 
(Figure 4B). RT-qPCR and western blotting showed 
that E2 increased the expression of hMLH1, but at 
less degree of hMSH2, at both mRNA and protein 
levels in pRST7-ER-β transfected SW480 cells 
(Figures 4C and 4D).
Correlations of serum E2 level with the expression of 
miRNA, ER-β, and MMR genes in human cancer 
tissue and adjacent non-cancer tissue 
To extend the above in vitro findings to actual 
patient, a group of 18 CRC patients were recruited 
to study the relationships of serum E2 level with 
miRNA, and mRNA expression of MMR and ER-β. 
Of the 18 patients, the serum E2 levels were 
between 8.93 and 69.16 pg/ml with a mean of 28.08 
pg/ml in the 9 male patients, while in the 9 female 
patients, the serum E2 levels were between 24.09 
and 70.18 pg/ml with a mean of 38.09 pg/ml. Both 
cancerous tissues and adjacent non-cancerous 
tissues were analyzed for four miRNAs (miR-135b, 
miR-31, miR-155, and miR-203) expression, and 
mRNA levels of ER-β, and MMR (hMLH1 and 
hMSH2). In cancer tissue, ΔCt and ΔΔCt (non- 
cancerous tissue as control) values of miR-135b (R2
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Figure 2. Effect of Estrogen (E2) on inhibiting the expression of miR-31, 
miR-135b and miR-155. Quantitative RT-PCR analysis indicates that E2
induced the down-regulation of mature miR-31, miR-155, and miR-135b 
with time, but not miR-223 in COLO205 cells (A). ICI182,780 reversed 
E2-induced inhibition of miR-31, miR-155 and miR-135b of COLO205 
cells (B). SW480 (C) and MCF7 (D) cells were treated with EtOH and E2
for 12 h, there were no significant changes in miR-31, miR-155 and 
miR-135b expression. Values presented were fold increase compared to 
EtOH for each miRNA and were calculated as described in ‘Materials
and Methods’ section. Mean± SD from 3 independent experiments. 
Significant differences between treated group versus EtOH control were 
calculated by ANOVA (*P＜ 0.05 and **P＜ 0.01). 
Figure 3. Effects of Estrogen (E2) on the expression of MLH1, MSH2
and ER-β mRNA. MLH1 and ER-β mRNA determined by RT-qPCR in 
COLO205 cells (A) treated with EtOH or 10-9 M of E2 for 0 h, 6 h, 12 h 
and 24 h. MLH1 and ER-β mRNA determined by RT-qPCR in COLO205 
cells (B) pre-treated with estrogen antagonist ICI 182.780 followed by 
EtOH or 10-9 M of E2 for 0 h and 12 h. Effects of E2 on MLH1, MSH2, and 
ER-β mRNA (C) measured by RT-qPCR in COLO205, SW480, and 
MCF7 cells. Cells were treated with EtOH, 10-10 and 10-9 M of E2 for 12 h. 
Mean± SD from 3 independent experiments. Significant differences 
between treated group versus EtOH control were calculated by ANOVA 
(*P＜ 0.05 and **P＜ 0.01). Effects of E2 on protein level expression 
(D) of MLH1, MSH2 and ER-β in COLO205, SW480, and MCF7 cells. 
= 0.716, P = 0.001; R2 = 0.675, P = 0.002) (Figure 
5A) and miR-31 (R2 = 0.567, P = 0.014; R2 = 0.561, 
P = 0.019) (Figure 5B) were significantly correlated 
with serum E2 concentrations, but this was not seen 
for miR-155 and miR-203 (R2 = 0.027, P = 0.515; R2
= 0.035, P = 0.459) (Figure 5C, respectively). 
    We also analyzed the correlations of E2 level with 
ER-β mRNA in the 18 CRC patients. In cancer 
tissue, the ΔCt and ΔΔCt (tumor versus non-tumor) 
values of ER-β mRNA were positively correlated (R2
= 0.583, P = 0.011; R2 = 0.525, P = 0.025) (Figure 
5D) with serum E2 concentrations, but hMLH1 and 
hMSH2 (Figure not shown) mRNA were not 
correlated with serum E2 concentrations.
    Since miR-155 has been shown to inhibit hMLH1 
expression in cultured malignant colonic epithelial 
cells (24), we analyzed the correlation of miR-135b, 
miR-31 and miR-155 with hMLH1 in the 18 CRC 
patients. In cancer tissue, the ΔΔCt values of 
hMLH1 mRNA were negatively correlated with that 
of miR-135b and miR-155 (data not show). This was 
not seen for miR-31 (data not show). As in vitro 
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Figure 4. Effect of Estrogen (E2) on MMR and several miRs in ER-β
over-expression cells. ERbeta protein expression (A) was not up-regu-
lated in vector transfected SW480 cells, whereas it was up-regulated in 
pRST7-ER-β transfected SW480 cells after 24 and 48 h of transfection. 
Quantitative RT-PCR analysis (B) indicates that E2 induced the 
down-regulation of mature miR-31, miR-155, and miR-135b in SW480- 
ERbeta cells, but not in vector transfected SW480 cells. Effects of E2 on 
MLH1 and MSH2 mRNA (C) measured by RT-qPCR in SW480- ERbeta
and vector cells. Mean± SD from 3 independent experiments. 
Significant differences between treated group versus EtOH control were 
calculated by ANOVA (*P＜ 0.05 and **P＜ 0.01). Effects of E2 on pro-
tein level expression (D) of MLH1 and MSH2 in SW480- ERbeta and 
vector cells. 
study cited above showed that E2 down-regulates 
the expression of miR-31, miR-155 and miR-135b in 
COLO205 cells through ER-β, we analyzed the 
correlation of ER-β mRNA with the expression of 
three miRNAs in cancer tissue. Only the ΔΔCt value 
of miR-135b was correlated with the ΔΔCt values of 
ER-β mRNA (data not show). 
Differential expression of miRNA and mRNA for ER-β 
and MLH1 in cancer versus adjacent non-cancer 
tissue from CRC patients
Finally, we analyzed the differential expression of 
miRNA in cancer versus adjacent non-cancer 
tissues. Interestingly, among the four tested miRNAs, 
miR-31, miR-155 and miR-135b (P＜ 0.05) were 
exhibited higher expressions, while there were no 
changes in miR-203 expression in cancer tissue 
compared with adjacent non-cancerous tissue 
(Figure 5E). Separate analyses of CRC patients 
showed that the ΔCt±SD of miR-31 was 11.2±
2.1 in cancer tissue and 12.7±1.9 in cancer- 
surrounding tissue (ANOVA, P = 0.032), the ΔCt±
SD of miR-155 was 9.8±1.6 in cancer tissue and 
11.2± 1.9 in cancer-surrounding tissue (ANOVA, P
= 0.024), and the ΔCt±SD of miR-135b was 9.5±
2.3 in cancer tissue and 11.1± 1.9 in cancer- 
surrounding tissue (ANOVA, P = 0.027). The results 
also indicated that the up-regulation of miR-135b 
was the most marked in cancer tissue (Figure 5E). 
Thus, miR-135b may be a potential marker for 
colorectal cancer.
    We also analyzed ER-β and MLH1 expression in 
cancer and adjacent non-cancer tissue. ΔCt±SD 
of ER-β mRNA was 10.2±1.4 in non- cancerous 
tissue and 8.9±1.9 in cancer tissue (ANOVA, P =
0.009), the ΔCt±SD of hMLH1 mRNA was 4.4±
1.5 in non-cancerous tissue and 3.8± 2.8 in cancer 
tissue (ANOVA, P = 0.436), the ΔCt±SD of hMSH2 
mRNA was 2.3± 1.5 in non-cancerous tissue and 
1.3±0.9 in cancer tissue (ANOVA, P = 0.086) 
(Figure 5F). Only ER-β showed significant changes 
(down-regulation) in cancerous versus adjacent 
non-cancerous tissue (Figure 5F). 
Discussion
This study revealed that E2 increased hMLH1 
expression in COLO205 cells, which could be 
inhibited by Estrogen antagonist ICI182,780. 
Previously we found that in healthy individuals, a 
strong positive correlation of E2 level with hMLH1 
expression in normal colonic epithelial cell was 
observed when serum E2 level was ＞ 45 pg/ml (Jin 
et al., 2010). Recent studies have indicated that 
estrogens can regulate miRNA expression in human 
breast cancer cells, endometrial stromal cells, and 
myometrial smooth muscle cells (Pan et al., 2007; 
Wickramasinghe et al., 2009). Based on these 
results, we hypothesize that E2 may regulate miRNA 
expression that may result in the regulation of 
hMLH1 expression in colonic epithelial cells. 
    In this study, COLO205, SW480 and MCF-7 cells 
were used. We found that E2 could induce apoptosis 
in ER-β expression COLO205 cells, but not in 
SW480 cells with very low levels of ER-β 
expression, and not in MCF-7 cells with high levels 
of ER-α expression. Further, in COLO205 cells E2 
down-regulated the expression of miR-31, miR-155 
and miR-135b and up-regulated mRNA and protein 
expression of ER-β and  hMLH1, which were 
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Figure 5. Correlations of serum Estrogen levels with miRNA and ER-β mRNA expression in CRC patients’ tissues. Correlations of serum Estrogen levels 
with miRNA and ER-β mRNA expression in CRC patients’ tissues. Serum Estrogen level was measured by ELISA assay whereas miRNA and ER-β
mRNA was analyzed by RT-qPCR assay as described in Material and Methods. Correlation of serum estrogen concentrations with miR135b (A) in tumor 
ΔCt and ΔΔ Ct (tumor versus non-tumor). Correlation of serum estrogen concentrations with miR-31 (B) in tumor ΔCt and ΔΔ Ct. Correlation between 
the expression levels of miR-155 as well as miR-203 (C) in patients’ cancer tissues and serum estrogen concentrations. Correlations of serum Estrogen 
concentrations with ER-β Mrna (D) in tumor ΔCt and ΔΔ Ct. Box plots with median, 25 th and 75 th percentiles, and range of expression levels of miR-31, 
miR-155, miR-135b, and miR-203 (E) in 18 tumor tissues relative to adjacent non-tumor tissue. Significant levels of differences were determined by 
ANOVA. Box plots with median, 25 th and 75 th percentiles, and range of expression levels of ER-β, hMLH1, hMLH2, (F) in 18 tumor tissues relative to 
adjacent non-tumor tissue. Significant levels of differences were determined by ANOVA (*P＜ 0.05 and **P＜ 0.01).
inhibited by ICI182,780. We also transfected the 
ER-β expressing plasmid to up-regulate ER-β 
expression in SW480 cells with very low levels of 
ER-β expression. In pRST7-ER-β transfected 
SW480 cells, E2 down-regulated the expression of 
miR-31, miR-155 and miR-135b and up-regulate 
mRNA and protein expression of hMLH were also 
observed. Therefore, we hypothesize that E2 may 
through ER-β to regulate MMR and miRNA 
expression. MiRNAs are reported to be able to 
down-regulate the core MMR heterodimer protein 
(Valeri et al., 2010a, 2010b). Therefore, E2 may 
up-regulate MMR gene through down-regulation of 
miR-31, miR-155 and miR-135b. Further, E2 appears 
to only up-regulate hMLH1 expression without the 
effect on the other core MMR gene, hMSH2, in 
COLO205 and transfected SW480 cells. Based on 
the data above, we hypothesize that during CRC 
carcinogenesis, E2 may through ER-β to inhibit 
miR-31, miR-155 and miR-135b expression, as a 
result leading to the up-regulation of MMR activity to 
prevent cancer progression (see Figure 6, hypothetical 
diagram).
    To verify the relationship of E2 and miRNA 
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Figure 6. A simplified hypothetical diagram of interrelationships between 
Estrogen, ER-β, miRNA, and MMR. Estrogen regulates miRNA ex-
pression through binding to ER-β. The resulted decreased miRNA ex-
pression may affect MMR function that eventually prevents the trans-
formation of normal colonic epithelium to cancer. ICI - estrogen inhibitor. 
expression in vivo, adjacent non-cancerous tissue, 
cancer tissue and serum samples from 18 CRC 
patients were analyzed. The results indicated that 
serum E2 levels were strongly and negatively 
correlated with miR-31 and miR-135b expression, 
but not for miR-155 expression in cancer tissue. We 
also found that in cancer tissue, hMLH1 mRNA 
levels were negatively correlated with that of miR-155 
and miR-135b expression, whereas ER-β mRNA 
levels were positively correlated with serum E2 
concentrations. Interestingly, only miR-135b has a 
significant correlation with serum E2 level, ER-β  and 
hMLH1 expression. Thus, we hypothesize that 
during cancer progression, a decreased estrogen 
and/or reduced ER-β  expression result in the 
increase of miR-135b, which contributes to MMR 
instability and eventually colorectal cancer carcino-
genesis (Figure 6). 
    This study showed that there was no significant 
correlation between hMLH1 expression and serum 
E2 level in CRC patients. Our previous study 
showed that in normal individuals, only when serum 
E2 levels were higher than 45 pg/ml, a strong 
positive correlation of E2 with hMLH1 gene expression 
was observed; and there was no significant 
correlation between hMLH1 expression and serum 
E2 level when E2 levels were lower (E2, ＜ 45 pg/ml) 
(Jin et al., 2010). In the current study of 18 CRC 
patients, only two patients’ serum E2 levels were 
higher than 45 pg/ml (a male, E2 = 69.16 pg/ml; a 
femail, E2 = 70.18 pg/ml). Therefore, the E2 
regulatory effects on MMR through ER-β and 
miRNA expression may be an important event that 
occurs early in tumorigenesis. 
    We observed that miR-135b expression was 
significantly higher in CRC tissues than in normal 
tissues, and miR-135b in exfoliated colonocytes 
isolated from feces was significantly higher in CRC 
patients than in healthy volunteers (Koga et al., 
2010; Wu et al., 2011). The first intron of the LEM 
domain containing 1 (LEMD1) gene contains 
miR-135b. Although the function of this gene is 
unclear, it has been reported that it exhibits high 
expression in CRC tissue compared to normal 
tissue (Yuki et al., 2004). As miR-135b is located on 
1q32.1 which frequently shows DNA copy number 
gain in CRC progression (Douglas et al., 2004; 
Jones et al., 2005), so the elevation of miR-135b 
level is common in CRC pathogenesis. The findings 
together may suggest that miR-135b could be a 
potential marker for CRC. 
    In summary, we found that E2 through ER-β 
down-regulates miRNAs expression, especially 
miR-135b that may result in up-regulaion of MMR 
activity. Additional studies are warranted to further 
examine the effect of these changes in colorectal 
carcinogenesis.
Methods
Cell culture and transfection
COLO205, SW480 and MCF-7 cells were purchased from 
ATCC, and cultured as previously described (Jin et al., 
2010). COLO205 and SW480 cells were incubated in dif-
ferent concentrations of estradiol E2 (Sigma-Aldrich., St 
Louis, MO) for 48 h; 100 nM of estrogen receptor antago-
nist ICI182,780 (Sigma-Aldrich., St Louis, MO) was then 
added followed by Annexin-V apoptosis assay. COLO205 
cells were treated with 10 nM E2 with a final volume of 
0.01% ethanol for 0 h, 6 h, 12 h and 24 h to determine 
mRNA expression, or for 0 h, 24 h and 48 h to determine 
protein expression. SW480 and MCF-7 cells were treated 
with EtOH, 1 nM or 10 nM E2, for 12 h alone or in combina-
tion with 100 nM ICI182,780 for 12 h. For the indicated ex-
periments, cells were pretreated with 100 nM ICI182,780 
for 6 h prior to EtOH or E2 treatment. SW480 Cells were 
seeded in 6-well plates (Corning Costar Corp., Cambridge, 
MA) in a final volume of 3.0 ml of culture medium for 24 h 
before transfection. Cells grown to 70% confluence in tissue 
culture plates were transiently transfected with an empty 
pRST7 vector and pRST7-ER-β (Addgene., Cambridge, 
MA) using Lipofectamine (Invitrogen., Carlsbad, CA) as de-
scribed by the manufacturer. The mammalian expression 
plasmid for ER-β (pRST7-ER-β) has been described pre-
viously (Hall and McDonnell, 1999). Western blotting was 
used to confirm the transfection efficiency after 24 h or 48 
h of transfection. After 24 h of transfection, SW480 (pERβ) 
and SW480 (vector) were treated with EtOH or 10 nM E2 
for 12 h. After incubation, cells were harvested and used 
for quantitative reverse transcription-PCR (RT-qPCR) and 
Western blotting.
Subjects 
A total of 18 patients - 9 males (age ranged from 31 to 73 
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yr, with a mean age of 53 yr) and 9 females (age ranged 
from 44 to 79 yr, with a mean age of 62 yr) diagnosed with 
CRC by colonoscopy were enrolled in this study from 
Beijing Military General Hospital. These patients were ran-
domly selected from patient pool of the hospital’s 
Gastrointestinal clinic; none of the subjects had undergone 
estrogen replacement therapy. Clinicopathologic character-
istics of the patients are presented (Supplemental Data 
Table S1). Blood was taken half an hour after colonoscopy 
for determining the serum E2 level. During colonoscopy, 
four or five samples from cancer tissues and adjacent 
non-cancer tissues, respectively, were obtained and stored 
in liquid nitrogen. The total RNA was isolated from frozen 
tissues with TRIzol (Invitrogen., Carlsbad, CA) according to 
the manufacture protocol. All tissue samples were re-
viewed and evaluated by a gastrointestinal pathological ex-
pert Sheng. In addition, the tissues used for RNA isolation 
were histologically identified to contain at least 70% of tu-
mor tissue. The study was approved by ethics committee 
of the Beijing Military General Hospital. Informed consent 
was obtained from all study subjects. 
Assessment of apoptosis by Annexin-V-FITC 
E2-induced apoptosis was measured with FITC-conjugated 
Annexin-V/PI assay kit (Abcam., Cambridge, MA) and flow 
cytometry. Cells were seeded in a 6-well plate, and follow-
ing pretreatment, incubated in serum-free medium contain-
ing different concentrations of E2 for 48 h. For estrogen re-
ceptor antagonist ICI182,780 inhibiting E2-induced apopto-
sis, COLO205 cells were pretreated with 100 nM of 
ICI182,780 for 6 h prior to EtOH or E2 treatment. 5×105 
cells were briefly washed with ice cold phosphate buffer 
solution, resuspended in 100 μl of binding buffer, and 
stained with 5 μl of FITC-conjugated Annexin-V (10 mg/ml) 
and 10 μl of PI (50 mg/ml). The cells were incubated for 15 
min at room temperature in the dark; 400 μl of binding buf-
fer was then added followed by analysis with a FACScan 
flow cytometry (Becton--Dickinson).
Real-time PCR 
The total RNA was extracted from cells of human can-
cer-surrounding tissue and cancer tissue with Trizol 
(Invitrogen., Carlsbad, CA). RNA concentrations were 
measured with a spectrophotometer (NanoDropTM 2000) 
and RNA integrity was analyzed with gel electrophoresis. 
Before cDNA was synthesized with RevertAidTM First Strand 
cDNA Synthesis Kits (Fermentas., Vilnius, Lithuania), total 
RNA (one mg) was treated with DNase I (Invitrogen., 
Carlsbad, CA) to remove DNA contamination. The RT pri-
mers of miRNAs were as follows: miR-31RT, GTCGTATC-
CAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC-
AGCTAT; miR-155RT, GTCGTATCCAGTGCAGGGTCCG-
AGGTATTCGCACTGGATACGACACCCCT; miR-135bRT, 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG-
GATACGACTCACAT; miR-203RT, GTCGTATCCAGTGCA-
GGGTCCGAGGTATTCGCACTGGATACGACCTAGTG; 
miR-223RT, GTCGTATCCAGTGCAGGGTCCGAGGTATT-
CGCACTGGATACGACTGGGGT.
    Expression of mRNA and mature miRNAs was de-
termined with the SYBR Green PCR Master Mix (TaKaRa., 
Dalian, China). miRNA expression was normalized accord-
ing to U6-snRNA of the 2-ΔΔCT-method (Pfaffl et al., 2001) 
and mRNA expression according to β-Actin. PCR was car-
ried out in a volume of 20 μl, and PCR conditions were as 
following: denaturing at 95oC for 30 s; denaturing at 95oC 
for 5 s, reannealing at 60oC for 34 s, elongation at 72oC for 
30 s, 40 cycles; finally elongation at 72oC for 5 min. 
Primers used in this study were as follows: miR-31, sense, 
5'-caAGGCAAGATGCTGGC-3'; miR-155, sense, 5'-cccTT-
AATGCTAATCGTGA-3'; miR-135b, sense, 5'-gctTATGGC-
TTTTCATTCCT-3'; miR-203, sense, 5'-ccaGTGAAATGTT-
TAGGAC-3'; miR-223, sense, 5'-cccTGTCAGTTTGTCAA-
AT-3'; miRNAs, anti-sense, 5'-GTGCAGGGTCCGAGGT-3'; 
U6, sense, 5'-GCTTCGGCAGCACATATACTAA-3'; anti-
sense, 5'-AACGCTTCACGAATTTGCGT-3'; hMLH1, sense, 
5'-TTCGTGGCAGGGGTTATTCG-3'; antisense, 5'-GCCT-
CCCTCTTTAACAATCACTT-3'; hMSH2, sense, 5'-GCTG-
GAAATAAGGCATCCAAGG-3'; anti-sense, 5'-CACCAATG-
GAAGCTGACATATCA-3'; β-actin, sense, 5'-CATGTACGT-
TGCTATCCAGGC-3'; anti-sense, 5'-CTCCTTAATGTCAC-
GCACGAT-3'.
    Real-time quantification was performed on 5 microRNAs 
(miR-31, miR-135b, miR-155, miR-203 and miR-223) with 
an Applied Biosystems 7500 Sequence detection system. 
These 5 candidate miRNAs were selected because 1) they 
exhibited high expression in cancer tissue compared with 
normal tissue (Sarver et al., 2009; Wu et al., 2011), 2) their 
high expressions (miR-155, -223,-31) were significantly as-
sociated with MSI-H status in CRC patient (Earle et al., 
2010), 3) they (miR-155) proved to regulate MMR genes 
(Valeri et al., 2010a), and 4) their expressions (miR-135b) 
in exfoliated colonocytes isolated from feces were sig-
nificantly higher in CRC patients than in healthy volunteers 
(Koga et al., 2010). All RT-qPCRs were performed in 
triplicates. The differences in tissue samples between 
groups are presented with ΔCt or ΔΔCt (normal tissue as 
control), indicating the differences between the Ct values of 
the interested miRNA and the serum E2 concentrations 
(Link et al., 2010). 
Western blotting 
Cells were washed with phosphate-buffered saline, and 
then lysed in extraction-buffer (Biosource, Camarillo, CA). 
Protein concentration was determined with BCA (Pierce, 
Rockford, IL). An aliquot of sample (25 mg) was separated 
on a 10% SDS-PAGE, and then transferred to a nitro-
cellulose membrane. The membrane was first incubated with 
the specific primary antibodies, ER-β, hMLH1 and hMSH2 
(Proteintech Group., Chicago, IL) followed by incubation 
with horseradish-peroxidase linked by immunoglobulin G, 
and then visualized with chemiluminescence. The bands 
detected in Western blotting were analyzed with the 
Totallab 2.0 software. 
Statistical analysis 
Data analysis was performed with SPSS 11.5 software. 
The differences between two groups were analyzed with 
Student's t test, whereas the differences between multiple 
groups (more than two) were analyzed with ANOVA test. 
Correlation analyses between serum E2 level and miRNA 
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expression, serum E2 level and mRNA expression, and 
miRNA and mRNA expression were performed with 
Pearson's test, and logarithmic regression was used to cal-
culate the R2 and to create a regression equation. There is 
a strong correlation if the Pearson's P is ＜ 0.5. R2 value ＞
0.3 was regarded as the fitting model. Two-sided P＜ 0.05 
was considered significant.
Supplemental data
Supplemental data include a table and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-44-12-02.pdf.
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